Ten years of progress in prostate cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 2, 2012, Pages 136-140

  Mohler, James L ^{a,b,c,d,e,f,g,h}  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d American Board of Urology   (United States)

^e AMERICAN COLLEGE OF SURGEONS   (United States)

^f NCCN Prostate Cancer Guidelines Panel   (United States)

^g Genitourinary Committee of the Alliance for Clinical Trials in Oncology   (United States)

^h Society for Basic Urologic Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; CABAZITAXEL; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; EARLY DIAGNOSIS; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; NOTE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; ROBOTIC SURGERY;

EID: 84856877820     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0016     Document Type: Note

References (20)

1. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
3. U.S. Prevntative Services Task Force: Screening for Prostate Cancer. USPSTF Program Office; Rockville, MD: August 2008 (current as of December 2011). Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspsprca.htm. Accessed January 17, 2012.
4. Drazer MW, Huo D, Schonberg MA, et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011;29:1736-1743.
5. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA 2006;296:2336-2342. (Pubitemid 44749361)
6. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
7. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809-816. (Pubitemid 351347736)
8. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-278. (Pubitemid 351430866)
9. Menon M, Hemal AK. Vattikuti Institute prostatectomy: a technique of robotic radical prostatectomy: experience in more than 1000 cases. J Endourol 2004;18:611-619; discussion, 619.
10. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-1141. (Pubitemid 44288788)
11. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-2190.
12. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-2670. (Pubitemid 351969209)
13. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-8169. (Pubitemid 46211550)
14. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448. (Pubitemid 38173980)
15. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-3748.
16. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-790.
17. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-4267. (Pubitemid 32848544)
18. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
19. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
20. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-1154.